Axsome Therapeutics Inc (NASDAQ: AXSM) is 1.60% higher on its value in year-to-date trading and has touched a low of $55.02 and a high of $98.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AXSM stock was last observed hovering at around $78.85 in the last trading session, with the day’s gains setting it 2.01%.
Currently trading at $80.86, the stock is 5.76% and -4.63% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.85 million and changing 2.55% at the moment leaves the stock 7.22% off its SMA200. AXSM registered 28.59% gain for a year compared to 6-month gain of 9.72%. The firm has a 50-day simple moving average (SMA 50) of $13.42 and a 200-day simple moving average (SMA200) of -$16.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.52% loss in the last 1 month and extending the period to 3 months gives it a 9.49%, and is 15.94% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.43% over the week and 4.72% over the month.
Axsome Therapeutics Inc (AXSM) has around 545 employees, a market worth around $3.83B and $270.60M in sales. Fwd P/E is 82.77. Profit margin for the company is -88.41%. Distance from 52-week low is 46.96% and -17.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.61%).
Axsome Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$1.19 with sales reaching $74.63M over the same period.The EPS is expected to grow by 30.31% this year, but quarterly earnings will post 40.60% year-over-year. Quarterly sales are estimated to grow 186.30% in year-over-year returns.
339 institutions hold shares in Axsome Therapeutics Inc (AXSM), with institutional investors hold 100.12% of the company’s shares. The shares outstanding are 47.35M, and float is at 38.78M with Short Float at 19.26%. Institutions hold 82.98% of the Float.
The top institutional shareholder in the company is RTW Investments LP with over 4.28 million shares valued at $307.87 million. The investor’s holdings represent 9.08% of the AXSM Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 3.74 million shares valued at $268.95 million to account for 7.93% of the shares outstanding. The other top investors are Blackrock Inc. which holds 2.72 million shares representing 5.77% and valued at over $195.71 million, while Fairmount Funds Management LLC holds 4.97% of the shares totaling 2.34 million with a market value of $168.51 million.
Axsome Therapeutics Inc (AXSM) Insider Activity
The most recent transaction is an insider sale by JEFFS ROGER, the company’s Director. SEC filings show that JEFFS ROGER sold 2,347 shares of the company’s common stock on Mar 15 ’24 at a price of $71.61 per share for a total of $0.17 million. Following the sale, the insider now owns 0.12 million shares.
Axsome Therapeutics Inc disclosed in a document filed with the SEC on Mar 14 ’24 that JEFFS ROGER (Director) sold a total of 29,976 shares of the company’s common stock. The trade occurred on Mar 14 ’24 and was made at $69.70 per share for $2.09 million. Following the transaction, the insider now directly holds 0.12 million shares of the AXSM stock.
Still, SEC filings show that on Sep 15 ’23, Coleman Mark (Director) disposed off 18,572 shares at an average price of $75.18 for $1.4 million. The insider now directly holds 403,856 shares of Axsome Therapeutics Inc (AXSM).
